BDTX · Black Diamond Therapeutics, Inc.

NasdaqHealthcareBiotechnology

Black Diamond Therapeutics Inc Is A Clinical-Stage Oncology Company Developing Masterkey Therapies That Target Families Of Oncogenic Mutations In Patients With Cancer. The Foundation Of Companies Has Been Built Upon A Deep Understanding Of Cancer Genetics, Onco-Protein Structure And Function, And Medicinal Chemistry. Its Clinical-Stage Program, Silevertinib (Formerly Bdtx-1535), A Brain-Penetrant, Fourth-Generation Epidermal Growth Factor Receptor (Egfr) Masterkey Inhibitor, Is Currently Being Studied In A Phase 2 Clinical Trial In Patients With Epidermal Growth Factor Receptor Mutant (Egfrm) Non-Small Cell Lung Cancer (Nsclc). The Company Manages Its Operations As A Single Operating Segment And Single Reportable Segment.

HealthcareNasdaqUSMid Float

$2.78

+69.5% latest move

Price & move as of the most recent catalyst (Mar 18) — not a live quote.

FLOAT

42.5M

FREE FLOAT %

74%

SHARES O/S

57.5M

MARKET CAP

$101.7M

EXCHANGE

Nasdaq

COUNTRY

BDTX Catalyst History

Corporate DealsMar 18, 2025 · 6:25pm ET

BDTXBlack Diamond Therapeutics, Inc.

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933

Agreement includes upfront payment and potential milestone payments.

Be early on the next BDTX spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →